COVALENT-111 Phase II Study Icovamenib in Type 2 Diabetes 52-Week Results October 7, 2025 COVALENT 111 - 52 Week Follow Up Conference Call October 7, 2025 1 Legal Disclaimer & Forward-Looking Statements Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial performance of Biomea Fusion, Inc. (the "Company") and involve known and unknown risks, uncertainties and other factors th ...